Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premorbid functioning as a predictor of outcome in early onset psychosis treated with Risperdal Consta
2005-004621-25Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of risperidone in schizophrenia and schizoaffective disorder, sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical response rate (PANSS). Started Nov 2005; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2005-004621-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004621-25.